Armistice Capital’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $131M | Buy |
8,876,000
+4,000
| +0% | +$59.2K | 2.27% | 3 |
|
|
2025
Q1 | $159M | Buy |
8,872,000
+1,514,000
| +21% | +$27.1M | 2.38% | 3 |
|
|
2024
Q4 | $128M | Sell |
7,358,000
-290,000
| -4% | -$5.05M | 1.75% | 3 |
|
|
2024
Q3 | $107M | Buy |
7,648,000
+148,000
| +2% | +$2.07M | 1.71% | 4 |
|
|
2024
Q2 | $61.7M | Hold |
7,500,000
| – | – | 0.78% | 14 |
|
|
2024
Q1 | $57.8M | Buy |
7,500,000
+116,000
| +2% | +$894K | 0.77% | 13 |
|
|
2023
Q4 | $66.4M | Sell |
7,384,000
-116,000
| -2% | -$1.04M | 0.91% | 16 |
|
|
2023
Q3 | $67.1M | Buy |
7,500,000
+50,000
| +0.7% | +$447K | 1.03% | 8 |
|
|
2023
Q2 | $114M | Buy |
7,450,000
+302,000
| +4% | +$4.64M | 1.66% | 5 |
|
|
2023
Q1 | $161M | Buy |
7,148,000
+736,000
| +11% | +$16.6M | 2.31% | 2 |
|
|
2022
Q4 | $135M | Buy |
6,412,000
+576,000
| +10% | +$12.1M | 2.35% | 3 |
|
|
2022
Q3 | $144M | Buy |
5,836,000
+516,000
| +10% | +$12.7M | 2.49% | 4 |
|
|
2022
Q2 | $129K | Buy |
5,320,000
+362,000
| +7% | +$8.77K | 2.25% | 8 |
|
|
2022
Q1 | $128M | Buy |
4,958,000
+880,000
| +22% | +$22.7M | 2.47% | 1 |
|
|
2021
Q4 | $127M | Sell |
4,078,000
-670,000
| -14% | -$20.8M | 2.07% | 3 |
|
|
2021
Q3 | $115M | Sell |
4,748,000
-1,000,000
| -17% | -$24.3M | 1.95% | 5 |
|
|
2021
Q2 | $83.9M | Buy |
5,748,000
+3,392,000
| +144% | +$49.5M | 1.5% | 13 |
|
|
2021
Q1 | $58.8M | Buy |
+2,356,000
| New | +$58.8M | 1.35% | 17 |
|
|
2015
Q1 | – | Sell |
-34,874
| Closed | -$427K | – | 29 |
|
|
2014
Q4 | $427K | Buy |
+34,874
| New | +$427K | 0.21% | 28 |
|